title: Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.
abstract: Meningiomas, the most frequent benign intracranial and intraspinal types of tumors are normally removed by surgery. Complications can occur when the tumor is critically localized and cannot be completely removed or when comorbidities of the mostly elder patients increase the general surgical risk. Thus, alternate medical treatment concepts for the therapy of meningiomas would be desirable. Curcumin, the active ingredient of the spice plant Curcuma longa has shown anti-tumorigenic actions in many different types of tumors and therefore, its effect on growth and apoptosis of meningioma cells was studied in the present paper. In vitro, treatment of the human Ben-Men-1 meningioma cell line and of a series of 21 primary human meningioma cell cultures with curcumin (1-20 μM) strongly reduced the proliferation in all cases in a dose dependent manner. Cell cycle analysis by fluorescence-activated cell sorting showed growth arrest at G2/M phase, which was confirmed by demonstrating the corresponding modulation of proteins involved in G2/M arrest by immunoblotting and/or confocal laser microscopy. High dosages (20, 50 μM) of curcumin induced a significant increase of apoptosis in Ben-Men-1 and primary meningioma cell cultures as demonstrated by morphological changes of cell nuclei, DNA fragmentation, translocation of cell membrane associated phosphatidyl serine and the induction of apoptotic-acting cleaved caspase-3. Our results suggest that the multi-targeting drug curcumin has potent anti-tumorigenic actions in meningioma cells and might therefore be a putative candidate for the pharmacological treatment of meningiomas.
authors.affiliation: Max Planck Institute of Psychiatry, Clinical Neuroendocrinology Group, Kraepelinstr 10, 80804 Munich, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Curic
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.forename: B
authors.initials: B
authors.lastname: Shan
authors.forename: C
authors.initials: C
authors.lastname: Schaaf
authors.forename: D
authors.initials: D
authors.lastname: Utpadel
authors.forename: M
authors.initials: M
authors.lastname: Lange
authors.forename: D
authors.initials: D
authors.lastname: Kuhlen
authors.forename: M J
authors.initials: MJ
authors.lastname: Perone
authors.forename: E
authors.initials: E
authors.lastname: Arzt
authors.forename: G K
authors.initials: GK
authors.lastname: Stalla
authors.forename: U
authors.initials: U
authors.lastname: Renner
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D003474:Curcumin / Q000494:pharmacology*; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D008577:Meningeal Neoplasms / Q000378:metabolism / Q000473:pathology*; D008579:Meningioma / Q000378:metabolism / Q000473:pathology*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D003474:Curcumin